This study identifies two independent architectural biomarkers associated with a shorter time to transformation in follicular lymphoma. CD14+ intratumoral cells localized to the follicle were associated with a shorter time to transformation; whereas, PD1+ cells present in a diffuse pattern had a shorter time to transformation compared to a follicular pattern. Multicolor immunohistochemistry and flow cytometry identified CD14+ cells as follicular dendritic cells (FDC). These FDC were shown to promote B cell growth. Two separate populations of PD1+ cells were identified; with PD1+/TIM3+ exhausted T cells associated with an inferior survival and shorter time to transformation. This is the first study to report an association of intratumoral 
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Background
Follicular lymphoma is the second most common type of Non-Hodgkin lymphoma. With a median overall survival of nearly 10 years, follicular lymphoma is classically thought of an indolent lymphoma that exhibits periods of disease remission and stability punctuated by intermittent relapses (1) . However, the disease course is often heterogeneous with some patients undergoing histologic transformation to an aggressive lymphoma, most often diffuse large B-cell lymphoma (DLBCL). Histologic transformation is often associated with rapid progression, refractoriness to treatment and an overall dismal prognosis (1-4). The incidence of transformation is variable ranging from 10-60% in different studies. The difference in incidence is largely due to differences in follow up, biopsy confirmation and inconsistent definitions of transformation (1, (3) (4) (5) (6) (7) (8) . The largest cohort reported an annual incidence of 3% (1) . Prognostic tools utilizing clinical and laboratory factors have been developed such as the follicular lymphoma international prognostic index (FLIPI) score that can predict risk of transformation at diagnosis (3, 9) .
Recent studies have demonstrated the prominent role the tumor microenvironment plays in disease severity and outcomes in follicular lymphoma (10) . Gene expression profiling from the Leukemia/Lymphoma Molecular Profiling Project (LLMPP) identified the non-malignant microenvironment immune cells rather than the tumor cells as predictive of clinical outcomes and behavior. One expression signature, immune-response 1, seemed to be derived from reactive Tcells and was associated with a favorable outcome. The other expression profile, immune response-2, included genes preferentially expressed by macrophages and dendritic cells that were associated with inferior survival (11) . IHC studies of the microenvironment have identified multiple immune subsets of interest (FOXP3+, PD1+, and CD4+/CD8+ ratio) that correlate with divergent outcomes (12) (13) (14) (15) (16) . However, these studies have often analyzed a few different IHC markers at a time and many of the studies have had led to contradictory results (12, 17) . Author Manuscript Published OnlineFirst on April 11, 2014 ; DOI: 10.1158/1078-0432.CCR- The association of an unfavorable outcome with genes expressed by macrophages and dendritic cells has led to increased interest in these immune subsets in follicular lymphoma patients. Farinha and others previously described that CD68+ macrophages or lymphoma associated macrophages (LAM) were correlated with inferior survival in their cohort (18) , though this effect was demonstrated to be overcome with treatment with rituximab (19) . CD14+ monocytes that are also HLA-DR low have been shown to have immunosuppressive effects in various clinical conditions and several solids tumors (20) (21) (22) (23) . Lin and colleagues (24) recently described the role of CD14+ monocytes in patients with B-cell NHL. They showed that increased levels of CD14+
HLA-DR low monocytes in the peripheral blood were associated with more advanced and aggressive disease and a shorter time to progression. Though these studies suggest an association of CD14+ cells with inferior outcomes they were based on peripheral blood and not tumor tissue. In addition, various other factors in the microenvironment such as PD1 expression have been identified as potentially impacting clinical outcomes in follicular lymphoma (13, 25) .
Recent studies have also demonstrated that the location of microenvironment cells with respect to the neoplastic follicle rather than the total cell quantity is predictive of clinical outcomes in follicular lymphoma (17) .
We hypothesized that intratumoral cells expressing CD14 or PD1 would be associated with a shorter time to transformation in patients with follicular lymphoma. To this end, we studied the clinical correlation between the prevalence and distribution of various components of the tumor microenvironment, including CD14+ cells, CD68+ macrophages, FOXP3+ and PD1+ cells, and the time to transformation and overall survival in a retrospective cohort of transformed follicular lymphoma patients. Beyond identifying these cells of interest, we also attempted to better characterize and identify the underlying immune cell type through multicolor IHC and flow cytometry.
Research. 
Methods:
Patients
Patients with follicular lymphoma that later transformed to DLBCL were identified from the Mayo Clinic Lymphoma Database. All samples were from the time of diagnosis and confirmed by a hematopathologist (AF) to be follicular lymphoma. Transformation was confirmed by biopsy and all histologies at transformation were consistent with DLBCL. 58 patients with tissue available at diagnosis were identified and included in this analysis. Clinical characteristics including age, sex, presence of B symptoms, stage, grade and laboratory parameters were collected at time of diagnosis. The various components of the FLIPI score (age >60, Stage 3 or 4, Hgb <12 mg/dL, > 4 nodal areas involved and LDH > upper limit normal) were collected to calculate FLIPI score for each patient. This study was approved through the Mayo Clinic institutional review board.
Immunohistochemistry
Paraffin-embedded tissue was obtained from Mayo Clinic Tissue Registry and serial 5 μm sections were used for IHC. The tissue was de-paraffinized with three changes of xylene and cleared through graded series of ethanol. Endogenous peroxidase was quenched by incubation in 50% methanol/H 2 0 2 and after rinsing with tap water, all sections were pretreated for 30 minutes with 50 mmol/L EDTA using a steamer and cooled for additional 5 minutes. All staining was done automatically on DAKO (Carpinteria, CA) Autostainer using the following antibodies to Author Manuscript Published OnlineFirst on April 11, 2014; DOI: 10.1158/1078-0432.CCR- or perifollicular area, whereas the diffuse pattern a majority of positive cells were not confined to the follicle. . Quantity and intensity of IHC stain were analyzed using a 0-3 scale. Assessment of IHC was done independently by two physicians (JPS and JMJ) with >90% concordance.
Because identifying a single antigen in isolation through IHC does not identify the underlying immune cell that is represented, co-expression of multiple antigens was visualized using a novel method devised by Glass and colleagues (26) . The resulting images captured were overlaid and each antigen assigned a color using Adobe Photoshop CS2 (Adobe Systems, Inc.; San Jose, 
Cell Culture
FDC enriched fractions were isolated as described in Schriever (27) et al with some modifications. Briefly, tonsils obtained from routine tonsillectomy were cut into small pieces and incubated for 1h at 37° with constant shaking in RPMI media containing 90ug/ml gentamicin , 2mg/ml collagenase (Worthington Biochemical, Lakewood, NJ) and 0.1mg/ml DNase (Sigma, St. 
Relationship between CD14+ cells and time to transformation
Paraffin tissue specimens were analyzed by pattern of location and cell content as described in the methods section. No relationship with TTT or OS was seen with the number or distribution of cells expressing FOXP3, CXCL3, CD21, CD68 or CD11c. The quantity of CD14+ cells was also not associated with TTT or OS; however, the location of CD14+ cells was predicative of time to transformation. As referenced in the methods, CD14+ cells were categorized based on pattern of location, follicular (n=13) and non-follicular (n=41) ( Figure 1A ). Patients with CD14+ cells localized to the follicle had a median TTT of 3.8 years compared to 5.9 years for those with a non-follicular staining pattern (p=0.027; Figure 1B ). The location of CD14+ cells was not associated with a significant difference in OS (p= 0.66; Figure 1C ). 
Relationship between PD1+ cells and time to transformation
undertaken to better identify which immune cells are represented by PD1+ staining. PD1+ cells are thought to be primarily T cells but it can also be expressed on activated B-cells (29) .
Multicolor IHC illustrated that PD1+ cells in our sample primarily expressed CD3 and did not colocalize with the B-cell marker CD19 ( Figure 3A) . To further analyze other markers of coexpression, flow cytometry was performed on follicular lymphoma samples with antibodies to CD3, CD19 and PD1. Again, CD3 was predominantly co-expressed with PD1 ( Figure 3B 
Identification of CD14+ cells
CD14 is often associated with monocytes, however CD14 is not exclusively expressed on monocytic cells and can be seen on other cell types (33) . We analyzed our CD14+ cell population using multicolor flow cytometry and IHC to various monocytic, macrophage and dendritic cell markers to better characterize the underlying cell type. Flow cytometry demonstrated minimal co-expression of CD14 with either CD68 or CD163 ( Figure 4A ). However, a substantial portion of CD14+ cells co-expressed CD21 and CD23, which are markers typically associated with follicular dendritic cells (FDC). Multicolor IHC demonstrated that CD21 and CD23 were co-expressed on nearly all CD14+ cells and were absent on CD68+ and CD163+ cells ( Figures 4B and C) . These results confirm the flow cytometry findings and suggest that rather than representing monocytes or macrophages, these CD14+ cells are FDC.
Follicular dendritic cells promote malignant cell viability
The prognostic role of FDC in follicular lymphoma is unclear. Our results suggest an association of inferior outcomes with an increase in CD14+ cells that localize to the follicle and whose the follicle were associated with a shorter time to transformation than those that did not.
Conversely, patient samples where PD1+ cells were no longer localized to the follicle were associated with a shorter time to transformation and inferior survival. These results were independent of each other and remained statistically significant after accounting for clinical factors such as the FLIPI score. This is the first report of an association of CD14+ cells predicting outcomes in patients with follicular lymphoma. Rather than the quantity of CD14+ cells, it was their location within the tumor and microenvironment that was predictive of outcome. CD14 is a lipopolysaccharide binding protein that can act as receptor for endotoxin that is often associated with monocytes (34) . Lymphoma associated monocytes have been associated with poor survival in follicular lymphoma (18, 35) and initially it was assumed the CD14+ cells represented intratumoral monocytes. However, further analysis through flow cytometry and multicolor IHC confirmed that the CD14+ intrafollicular cells were distinct from monocytes or macrophages and represented FDC. Though FDC are typically identified by CD21, CD23 and CD35 surface markers they have also previously been associated with CD14 as well (36) . CD14+ monocytes are thought to be immunosuppressive and their presence is associated with more aggressive tumors in NHL (24); however the role of CD14+ cells that are representative of a FDC phenotype is unknown.
Previous gene expression profiles of follicular lymphoma patients identified that an increase in genes expressed by dendritic cells was associated with poor overall survival (11) . A recent study assessed the prognostic role of FDC in follicular lymphoma based on the extent of follicular dendritic cells (37) . They found no association with clinical outcomes; however, this study focused on all FDC using a pan-FDC antibody where as in our study the predictive component was limited to CD14+ cells. Similarly, in this current study no association with clinical outcomes was seen when the more common FDC marker CD21+ was compared, this suggests that the CD14+ FDC 
of interest may represent a unique subset of FDC. To clarify the role of FDC in follicular lymphoma we co-cultured FDC and malignant B -cells and demonstrated the presence of FDC cells led to increased B-cell viability. Others have also found that FDC promote the proliferation and prevent apoptosis of transformed malignant B-cells (38, 39) . Though there are limitations in these studies as tonsil derived FDC were utilized and viability rather than transformation was measured, these results confirm these previous findings and provide a biologic rationale for the observation that CD14+ FDC localized to the follicle are associated with a shorter time to transformation.
In addition to CD14+ FDC, PD1+ cells were found to be strongly correlated with clinical outcomes. Patients whose biopsies demonstrated PD1+ cells that localized to the follicle had a significantly prolonged time to transformation and overall survival compared to those with a diffuse pattern of PD1+ cells. The role of PD1 in solid tumors is well recognized with some solid tumors expressing PD-L1 and this ligand for PD1 being associated with a poor prognosis possibly through a decrease in tumor immune surveillance (40, 41) . Previous analyses of PD1+ cells in follicular lymphoma have yielded conflicting results. Two studies supported that increased levels of PD1+ cells were associated with superior outcomes including a decreased risk of transformation (13, 25) . However, additional studies have not confirmed the correlation between improved outcome and an increased number of PD1+ cells (42) . In fact, some studies have found that increased PD1+ cells are associated with an inferior survival in follicular lymphoma (15) .
Though this study found no association between the TTT and the quantity of PD1+ cell content, it, like other microenvironment analyses, found an association between the location within the microenvironment and patient outcomes (14, 17, 43) . When reviewing the previous analyses that did find a positive association of PD1+ cells and survival, in one study >90% of PD1+ cells were localized to the follicle and in the other the results were accentuated when the analysis was This study did not find an association with increased quantity of CD68+ macrophages or FOXP3+ cells and clinical outcomes as others have previously reported (12, 18) . This could be related to sample size, variation in treatment received as well as difference in technique and interpretation of IHC. However, follow up studies of the significance of increased CD68+ macrophages have been contradictory (19, 43, 44) . Similarly, further studies have not confirmed the association of increased FOXP3+ cells and superior outcomes in follicular lymphoma (17, 44) ; in fact, Carreras et al noted that after adjusting for the presence of PD1+ cells, FOXP3 was no longer associated with improved survival (13) . In addition, this study involved a majority of patients treated prior to the rituximab era. Thus, our microenvironment findings do not reflect the potential effects of rituximab treatment and previous studies have demonstrated that the introduction of rituximab can affect microenvironment associations (19) . Furthermore, previous studies have documented a constant annual rate of transformation rather than a dynamic rate of transformation, as seen in this study, which may suggest an evolving change in the microenvironment . The microenvironment factors identified in our analysis therefore likely contribute to transformation but may not be comprehensive. It is conceivable that the interactions and effects of PD1 and CD14 cells with other immune cells and/or the tumor itself lead to a more stepwise development of transformation.
This study identifies two independent factors of the follicular lymphoma microenvironment that are associated with a shorter time to transformation. In both instances it is the pattern of location rather than quantity of PD1+ and CD14+ cells that is predictive of clinical outcomes. This study is the first to report an association between CD14+ FDC and clinical outcomes in follicular lymphoma. The study also provides additional understanding to the complex interaction of PD1 in follicular lymphoma. We find that PD1+ T FH . FDC increase CD19 + follicular lymphoma cell survival FDC were co-cultured with follicular lymphoma patient samples using positively selected CD19+ cells at a ratio of 2.5:1. After 48 hours the viability of the CD19+ follicular lymphoma cells was assessed by Annexin V/PI. The presence of FDC was associated with significant increase in viability of CD19+ cells (p=0.003). B) Sequential biopsies from diagnosis to transformation from two representative patient samples demonstrate a transition from PD1+ cells in the follicle to a diffuse pattern as patient nears transformation. C) CD14+ cells change across time from nonfollicular to follicular pattern.
